Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study

• Main Authors: Xue Zhao (Author), Hongzhong Liu (Author), Wei Tian (Author), Ligang Fang (Author), Mengyang Yu (Author), Xiaofei Wu (Author), Aijing Liu (Author), Ruijie Wan (Author), Li Li (Author), Jinghui Luo (Author), Yuqiong Li (Author), Bo Liu (Author), Yu He (Author), Xiaowen Chen (Author), Yuan Li (Author), Donghong Xu (Author), Hongyun Wang (Author), Xiaohong Han (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objectives: Aficamten is a selective, small-molecule allosteric inhibitor of cardiac sarcomere being developed as a chronic oral treatment for patients with symptomatic obstructive hypertrophic cardiomyopathy. This was the first-in-Chinese study aiming to investigate the safety, tolerability, pharma...